Sign In
Buy SHIEF
$0.0580
+0 (+0%)
At Close: Aug 10, 2026
Shield Therapeutics files for South Korean regulatory approval for Accrufer
02:57am, Tuesday, 28'th May 2024
Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF)'s partner, Korea Pharma, has filed a New Drug Application (NDA) for Accrufer with the country's Ministry of Food and Drug Safety. This filing is a cruc
Peel Hunt to update Shield Therapeutics' forecast model
06:56am, Monday, 13'th May 2024
Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF)'s full-year results, where the company reported a trebling of total revenues, were consistent with a recent first-quarter business update, said broker Pe
Shield Therapeutics revenues almost treble as Accrufer sales ramp up
11:20am, Friday, 10'th May 2024
Shield Therapeutics revenues almost trebled in 2023 as sales of its Accrufer/Feraccru iron deficiency treatment ramped up in the US. Revenues rose to US$17.5 million, a 2.8 times increase over the pr
Shield Therapeutics reiterates cash flow positive target as it continues to make US headway
02:50am, Tuesday, 30'th Apr 2024
Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF), the commercial-stage pharmaceutical company, confirmed it is still on course to be cash flow positive in the second half of next year as revealed its c
Shield Therapeutics hails breakthrough year
03:11am, Wednesday, 21'st Feb 2024
Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) delivered a nearly three-fold increase in its revenues and revealed a strong bank balance as it said it aimed to be cash flow positive in the second half
Shield Therapeutics is "bearing fruit", says Cavendish
11:07am, Wednesday, 13'th Dec 2023
Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF)'s third-quarter trading update for Accrufer in the US market shows its tie-up with Viatris and expanded sales team are “bearing fruit”, according to
Shield makes significant commercial traction with prescriptions up 76%
02:53am, Thursday, 07'th Dec 2023
Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF), the commercial-stage specailist pharma company known for its Accrufer iron deficiency treatment, has seen significant growth in the US market in the
Shield Therapeutics gets positive initiation from broker Stifel
11:19am, Thursday, 23'rd Nov 2023
With the growth in popularity of Shield Therapeutics PLC's (AIM:STX, OTCQX:SHIEF) Accrufer prescription iron medicine, Stifel has initiated coverage with a 'buy' rating on the company. Accrufer, whi
Shield Therapeutics launches executive search process as CFO steps down
04:41am, Thursday, 12'th Oct 2023
Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) has announced that chief financial officer Hans-Peter Rudolf is stepping down from his position to pursue other opportunities. Paul Spoors, group company
Shield Therapeutics: A case of cautious optimism amid revised guidance
06:54am, Tuesday, 03'rd Oct 2023
Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF), which has developed a best-in-class anaemia treatment, has been going through the growing pains associated with a business at the formative stage of it
Shield Therapeutics raises funds to accelerate commercial opportunity for Accrufer iron deficiency treatment in US market
04:29am, Thursday, 28'th Sep 2023
Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) is raising up to $27.5 million of new funds to support its development of Accrufer, its iron deficiency treatment, with proceeds earmarked to accelerate
Small-cap Movers: GSTechnologies takes Canada plunge, Shield Therapeutics leads in life sciences
06:11am, Sunday, 23'rd Jul 2023
There is life in the cryptocurrency sector yet, so it may seem. At least for GSTechnologies Ltd (LSE:GST), the London-listed financial technology small cap historically focused on the esoteric blockch
Shield Therapeutics reports 173% Accrufer prescription growth
03:04am, Thursday, 20'th Jul 2023
Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) said its Accrufer iron deficiency treatment saw 173% growth in prescriptions in the second quarter, or a 50% improvement on the first. Total prescription
Shield Therapeutics ready to go full throttle in the US
02:56am, Thursday, 27'th Apr 2023
Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) said it is ‘very' optimistic about the future as it gears up for a full US commercial push of its lead asset, the iron deficiency drug Accrufa. With ca
Shield Therapeutics appoints chief commercial officer as group readies for US sales offensive
02:47am, Wednesday, 05'th Apr 2023
Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF), the developer of a breakthrough oral drug for iron deficiency, has announced the appointment of industry veteran Andy Hurley as its chief commercial o
